Status:
COMPLETED
Cost-effectiveness of RAMP-HT for Patients With Uncontrolled Hypertension in Hong Kong
Lead Sponsor:
The University of Hong Kong
Conditions:
Hypertension
Cost Effectiveness
Eligibility:
All Genders
18-79 years
Brief Summary
Hypertension (HT) is an important risk factor for stroke, coronary heart disease (CHD), heart failure and renal diseases, and the leading risk factor of global disease burden. A multitude of intervent...
Detailed Description
Aim and objectives: The aim of this study is to evaluate the cost-effectiveness of the RAMP-HT of the HA in primary care patients with uncontrolled hypertension. The objectives are to: 1. Evaluate ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Age ≥ 18 years old and \< 80 years old
- Coded with ICPC-2 of K86 on or before baseline\*
- Had uncontrolled blood pressure (i.e. average Systolic Blood Pressure (SBP) ≥ 140mmHg OR Diastolic Blood Pressure (DBP) ≥ 90mmHg between 6 months before and 3 months after baseline\*)
- Exclusion criteria:
- Patients who had a diagnosis of any HT complications defined by relevant ICPC-2 and/or ICD-9-CM diagnosis codes on or before baseline\*
- Patients diagnosed to have Diabetes Mellitus (DM) on or before 31 March 2017, defined by ICPC-2 codes of T89 or T90
- Patients exclusively managed by Specialist Out-Patient Clinic (SOPC) on or before baseline\*
- Baseline: date of RAMP-HT enrolment for RAMP-HT cohort, and 31 March 2012 for usual care cohort
Exclusion
Key Trial Info
Start Date :
August 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2019
Estimated Enrollment :
158322 Patients enrolled
Trial Details
Trial ID
NCT03301194
Start Date
August 1 2016
End Date
January 31 2019
Last Update
May 3 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Hong Kong
Hong Kong, Hong Kong